“Our proven GPCR structure-based drug discovery platform enabled us to rapidly advance ACCG-2671 as the lead amylin receptor agonist. We are now developing a series of amylin-based drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback